Waters (NYSE:WAT – Get Free Report) is expected to post its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to announce earnings of $4.00 per share and revenue of $1.75 billion for the quarter. Waters has set its Q3 2026 guidance at 3.950-4.050 EPS and its FY 2026 guidance at 14.450-14.650 EPS. Individuals can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:00 AM ET.
Waters (NYSE:WAT – Get Free Report) last posted its earnings results on Tuesday, August 4th. The medical instruments supplier reported $3.05 earnings per share for the quarter, beating the consensus estimate of $3.01 by $0.04. The business had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.62 billion. Waters had a return on equity of 11.27% and a net margin of 3.58%. The business’s quarterly revenue was up 113.3% on a year-over-year basis. During the same period in the previous year, the business earned $2.95 EPS. On average, analysts expect Waters to post $14.56 EPS for the current fiscal year and $16.56 EPS for the next fiscal year.
Waters Stock Performance
Shares of WAT opened at $456.17 on Tuesday. The company’s 50 day simple moving average is $425.31 and its 200-day simple moving average is $369.05. The firm has a market cap of $44.82 billion, a PE ratio of 113.76, a price-to-earnings-growth ratio of 2.64 and a beta of 1.15. Waters has a 12-month low of $282.77 and a 12-month high of $465.36. The company has a current ratio of 1.86, a quick ratio of 1.29 and a debt-to-equity ratio of 0.32.
Insiders Place Their Bets
In other Waters news, Director Christopher Kuebler sold 3,626 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $397.94, for a total value of $1,442,930.44. Following the completion of the sale, the director owned 17,808 shares of the company’s stock, valued at approximately $7,086,515.52. This trade represents a 16.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.31% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
A number of equities research analysts have recently commented on WAT shares. Wells Fargo & Company upped their target price on shares of Waters from $370.00 to $400.00 and gave the company an “equal weight” rating in a report on Wednesday, August 5th. Sanford C. Bernstein raised their price target on Waters from $435.00 to $450.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. UBS Group upgraded Waters from a “neutral” rating to a “buy” rating and boosted their price target for the company from $375.00 to $490.00 in a research report on Wednesday, September 9th. Deutsche Bank Aktiengesellschaft boosted their price target on Waters from $400.00 to $440.00 in a research report on Thursday, October 15th. Finally, Wall Street Zen raised Waters from a “hold” rating to a “buy” rating in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $457.50.
Get Our Latest Report on Waters
Waters Company Profile
Waters Corporation (NYSE:WAT) develops and manufactures analytical technologies used to measure, identify and characterize chemical and biological substances. Its customers include pharmaceutical and biotechnology companies, industrial manufacturers, academic and government laboratories, and organizations involved in food, environmental and clinical testing.
The company’s product portfolio includes high-performance liquid chromatography and ultra-performance liquid chromatography systems, mass spectrometers, chromatography columns and consumables, and laboratory software for data management and analysis.
Featured Articles
- Five stocks we like better than Waters
- Verizon’s Q3 Results Show Why SpaceX’s Spectrum Grab Isn’t a Major Threat
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.
